Table.

Summary of patient demographics and treatments received that were not specific to secondary haemophagocytic lymphohistiocytosis by patient

	Sex	Age, years	Notable comorbidities	Time from admission to secondary haemophagocytic lymphohistiocytosis diagnosis, days	Peak ferritin, μg/L	Mechanical ventilation	Inotropic support	Renal replacement therapy	Other treatments received	Final patient outcome (days to death or discharge)
Patient 1	Male	40	Acute lymphoblastic leukaemia	28	76 225	Yes	No	No	Piperacillin and tazobactam preparation, meropenem, and liposomal amphotericin B	Died (74)
Patient 2	Male	28	Recurrent pneumonias	6	3164	Yes	Yes	No	Cefuroxime	Died (7)
Patient 3	Male	36	Acute lymphoblastic leukaemia	12	17 085	No	No	No	Meropenem, liposomal amphotericin B, and filgrastim	Discharged (31)
Patient 4	Male	36	No medical history	1	5736	Yes	Yes	No	Potassium clavulanate and amoxicillin preparation	Discharged (16)
Patient 5	Female	60	Systemic lupus erythematosus	3	12 402	Yes	Yes	Yes	Glucocorticoids (ie, for systemic lupus erythematosus)	Died (42)
Patient 6	Male	56	Asthma	3	9245	Yes	Yes	No	Potassium clavulanate and amoxicillin preparation and meropenem	Discharged (43)
Patient 7	Male	63	Type 2 diabetes and atrial fibrillation	0	17 790	Yes	Yes	No	Potassium clavulanate and amoxicillin preparation and piperacillin and tazobactam preparation	Discharged (11)
Patient 8	Male	54	Asthma	0	19 078	Yes	Yes	Yes	Glucocorticoids, potassium clavulanate and amoxicillin preparation, piperacillin and tazobactam preparation, and meropenem	Died (32)
Patient 9	Male	52	Previous deep vein thrombosis	1	12 607	Yes	Yes	Yes	Piperacillin and tazobactam preparation, clarithromycin, meropenem, vancomycin, and ciprofloxacin	Discharged (96)
Patient 10	Female	22	Sickle cell trait	9	45 864	No	Yes	No	Piperacillin and tazobactam preparation, ciprofloxacin, clindamycin, metronidazole, meropenem, linezolid, ceftazidime, and fluconazole	Discharged (40)